Nanoparticle delivery of cardioprotective therapies.
Nanoparticle delivery of cardioprotective therapies.
复制标题
DOI：
--
复制
发表时间：
2020-02
期刊：
影响因子：
--
通讯作者：
A. Mendez-Fernandez;H. Cabrera-Fuentes;Bhaarathy Velmurugan;Jason Irei;W. Boisvert;Shengjie Lu;D. Hausenloy
中科院分区：
文献类型：
--
作者：
A. Mendez-Fernandez;H. Cabrera-Fuentes;Bhaarathy Velmurugan;Jason Irei;W. Boisvert;Shengjie Lu;D. Hausenloy
急性心肌梗死（AMI）和随之而来的心力衰竭（HF）是世界范围内死亡和残疾的主要原因。至关重要的是，除了心肌再灌注外，目前还没有有效的治疗方法来减少心肌梗死（MI）的大小并预防AMI后的HF。因此，发现新的心脏保护疗法来减少心肌梗死的大小，并预防AMI患者的HF是一个未被满足的需求。尽管大量的治疗方法在实验研究中被证明可以减少心肌梗死的大小，但大多数治疗方法都未能使AMI患者受益。在以往的临床心脏保护研究中，AMI后未能向缺血心脏提供足够浓度的心脏保护治疗是缺乏成功的主要因素。因此，需要新的策略来改善AMI后缺血性心脏的心脏保护治疗。在这方面，纳米颗粒已成为改善心脏保护疗法的生物利用度、传递和释放的药物传递系统，并应在减少心肌梗死大小和预防心衰方面提高疗效。在本文中，我们综述了目前可用的纳米颗粒，其中一些已获得fda批准，用于心血管疾病和心脏保护的药物传递系统。
Acute myocardial infarction (AMI), and the heart failure (HF) that often follows, are leading causes of death and disability worldwide. Crucially, there are currently no effective treatments, other than myocardial reperfusion, for reducing myocardial infarct (MI) size and preventing HF following AMI. Thus, there is an unmet need to discover novel cardioprotective therapies to reduce MI size, and prevent HF in AMI patients. Although a large number of therapies have been shown to reduce MI size in experimental studies, the majority have failed to benefit AMI patients. Failure to deliver cardioprotective therapy to the ischemic heart in sufficient concentrations following AMI is a major factor for the lack of success observed in previous clinical cardioprotection studies. Therefore, new strategies are needed to improve the delivery of cardioprotective therapies to the ischemic heart following AMI. In this regard, nanoparticles have emerged as drug delivery systems for improving the bioavailability, delivery, and release of cardioprotective therapies, and should result in improved efficacy in terms of reducing MI size and preventing HF. In this article, we provide a review of currently available nanoparticles, some of which have been FDA-approved, in terms of their use as drug delivery systems in cardiovascular disease and cardioprotection.